Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targeted Oncologic Therapies Demand New Approach to Phase II/III Trials

Executive Summary

Targeted cancer therapies should be studied in large Phase II programs that incorporate biomarkers, a panelist said at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla

You may also be interested in...



Better, Faster, Smaller: Personalized Medicine Could Bring R&D Savings

PHILADELPHIA - One near-term benefit of adopting a personalized medicine approach to drug development would be a lower cost for clinical trials by conducting smaller, faster studies that will produce better results and help companies make go/ no go decisions sooner, according to speakers at the Wharton Health Care Business Conference

Better, Faster, Smaller: Personalized Medicine Could Bring R&D Savings

PHILADELPHIA - One near-term benefit of adopting a personalized medicine approach to drug development would be a lower cost for clinical trials by conducting smaller, faster studies that will produce better results and help companies make go/ no go decisions sooner, according to speakers at the Wharton Health Care Business Conference

Key To Better Oncology Trials Could Be Better Historical Controls, Study Says

The solution to poor clinical trial design in oncology trials could be better calculation of historical control rates used to create response measures, according to a study appearing in Clinical Cancer Research

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel